MULTILATERAL EVALUATION MECHANISM (MEM)

Evaluation Survey (Draft)

Sixth Evaluation Round
Introduction

This Evaluation Survey, approved by the Inter-American Drug Abuse Control Commission (CICAD), is the primary communication tool permitting dialogue between member states and the Governmental Expert Group (GEG), in order to collect information from member states for the Multilateral Evaluation Mechanism Sixth Round evaluation process.

The Evaluation Survey is divided into five chapters, in accordance with the structure of the Hemispheric Drug Strategy and its Plan of Action, 2011-2015, as follows: Institutional Strengthening, Demand Reduction, Supply Reduction, Control Measures and International Cooperation. Each chapter includes the relevant recommendations, as agreed to by CICAD, as well as questions designed to obtain information that will allow the Experts to evaluate the level of progress made in the implementation of each Recommendation.

The questions are designed to allow member states to respond directly, providing concrete information and/or statistics. In addition, in most cases, a brief explanation is requested, allowing the country to provide additional details. Each country will have the opportunity to update both quantitative and qualitative information, prior to the preparation of the final draft report, which will allow for a more complete evaluation.

In order to facilitate understanding and standardize the meaning of some terms as they relate to the MEM evaluation process, definitions have been included. Terms are identified by a footnote the first time they appear in the survey, and their meaning and context are further explained at the bottom of the page where they appear.

It is important to highlight that in addition to the spaces provided to submit the required information, at the end of each recommendation, a section entitled “Context observations” has been included; this space is intended to provide member states with the opportunity to provide supplementary information that they believe is relevant. Therefore, member states are urged to utilize this space to provide context regarding their individual situations, in order to allow the evaluator to better understand the characteristics and particular situations of each country, as they relate to the different topics addressed. In addition, each country has the option to include a Reference Document to contextualize their situations and the challenges faced in addressing the drug problem, using the attached outline. Although submission of this document is not obligatory, it is highly recommended.

Each NCE is requested to comply with the established timeframe, as well as the deadlines for submission of information. Submission of all required information is appreciated, as it will allow for the most accurate evaluation possible.
RECOMMENDATION 1

Establish and/or strengthen national drug authorities, placing them at a high political level, with the mission to coordinate the effective planning and implementation of national drug policies.

1. Does your country have a national drug authority?

   Yes  No

   If yes, please indicate:

   1.a. Name of national authority.

   1.b. Year established.

   1.c. Position within the state's administrative structure.

   1.d. Agencies that comprise the governing level of the national authority.

2. Does the national authority have a legal basis?

   Yes  No

3. Is there an annual budget for the national authority?

   Yes  No
If yes:

3.a. Is the national authority’s budget integrated with the budget of another government agency or is it independent?

3.b. What is the amount of the annual budget for years 2011-2014?

<table>
<thead>
<tr>
<th>Year</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount of the annual budget</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. What areas does the national authority coordinate?

<table>
<thead>
<tr>
<th>Area</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demand reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supply reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative, integral and sustainable development programs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug observatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International cooperation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other. Please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If your national drug authority does not carry out coordination of activities in question 4, please provide the following information:

5. Does the national authority have a central technical office to carry out its mandates?

Yes [ ]  No [ ]

If yes, please provide the following information:

5.a. Name of central technical office.

5.b. Year established.

__________________________
5.c. Position within the state’s administrative structure.

5.d. Agencies that comprise the governing level of the central technical office.

6. Does your government have a coordination mechanism to carry out the effective planning and implementation of national drug policies?

Yes  No

If yes:

6.a. Who oversees it?

6.b. Which agencies are involved in the planning?

6.c. Which agencies are involved in the implementation?

7. Does the coordination mechanism reach all levels of government (e.g., central, departmental, provincial)?

Yes  No

If yes:

7.a. How does it function?
8. Does the coordination mechanism reach the other necessary stakeholders (e.g., NGOs, universities, research bodies)?

   Yes   No

If yes:

8.a. How does it function?

9. Does the coordination mechanism cover all the areas addressed in the national drug policies?

<table>
<thead>
<tr>
<th>Area</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demand reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supply reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative, integral and sustainable development programs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug observatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International cooperation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other. Please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CONTEXT OBSERVATIONS FOR RECOMMENDATION 1:


AGENCY AND OFFICIAL PROVIDING INFORMATION:


INSTITUTIONAL STRENGTHENING

RECOMMENDATION 2

Design, implement, strengthen and update national evidence-based strategies and policies on drugs.

10. Does your country have a National Drug Plan/Strategy?

  Yes  No

  If yes:

  10.a. What period of time does the National Drug Plan/Strategy cover?

  10.b. By whom was approval granted (e.g., Cabinet of Ministers, Parliament, other)?

  If no:

  10.c. What is the current status of the National Drug Plan/Strategy?

<table>
<thead>
<tr>
<th>Status</th>
<th>Yes</th>
<th>No</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drafted but pending approval</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Being drafted – (Please provide timeframe for completion and approval)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Its period has expired</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In force by extension of the previous National Drug Plan/Strategy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No action has been taken</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

11. Does the National Drug Plan/Strategy include the areas of demand reduction, supply reduction, control measures, and international cooperation?

  Yes  No
If yes:

11.a. What are the primary objectives of each area?

If no:

11.b. Does the proposed National Drug Plan/Strategy include these areas?

12. Does the National Drug Plan/Strategy have an assigned budget?

Yes  No

If yes:

12.a. What is the source of funding?

12.b. What is the amount budgeted for the next 4 fiscal years?

<table>
<thead>
<tr>
<th>Year</th>
<th>20__</th>
<th>20__</th>
<th>20__</th>
<th>20__</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount budgeted for the fiscal year</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If no:

12.c. How will the activities in the National Drug Plan/Strategy be funded?
13. Are all the relevant actors\(^1\) from priority areas\(^2\) involved in designing and drafting the National Drug Plan/Strategy?

Yes ☐ No ☐

14. Are all relevant actors from priority areas involved in executing the National Drug Plan/Strategy?

Yes ☐ No ☐

15. Has responsibility for various areas of the National Drug Plan/Strategy been decentralized, or are there other decentralized plans that align to the National Drug Plan/Strategy, to facilitate efficient implementation?

Yes ☐ No ☐

If yes:

15.a. How many state or regional bodies execute drug plans?


15.b. How many departmental or provincial governments execute drug plans?


15.c. How many municipal and/or local governments execute drug plans?


16. Does the National Drug Plan/Strategy have a monitoring and evaluation framework?

Yes ☐ No ☐

---

\(^1\) Relevant actors: Includes civil society, scientific community, university based researchers, government at the national, regional and local levels.

\(^2\) Priority areas: E.g., Institutional strengthening, demand reduction, supply reduction, control measures and international cooperation.
If yes:

16.a. What is the process and time frame for monitoring and evaluation?

17. Is the monitoring and evaluation of the National Drug Plan/Strategy undertaken by the staff responsible for its oversight or by an independent evaluator?

17.a. If the monitoring and evaluation of the National Drug Plan/Strategy is undertaken by the staff of the oversight agency, is the staff of the agency adequately trained to undertake this function:

Yes  No

17.b. If the monitoring and evaluation of the National Drug Plan/Strategy is undertaken by an independent evaluator, what resources will be considered for selection of this evaluator (e.g., consultants, academic Institutions):

18. What is the outcome of the evaluation of policies, plans and programs (e.g., identified gaps and activities required to strengthen the National Drug Plan/Strategy):

19. What activities have been undertaken to update policies, plans and programs in accordance with the evaluation of the National Drug Plan/Strategy:
CONTEXT OBSERVATIONS FOR RECOMMENDATION 2:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
INSTITUTIONAL STRENGTHENING

RECOMMENDATION 3
Establish and/or strengthen National Observatories on Drugs or similar technical offices to develop national drug information systems and foster scientific research on this subject.

20. Does your government have a National Drug Observatory or similar technical office (a centralized office at the national/federal level) that organizes, and/or carries out studies and/or compiles, and/or coordinates drug-related statistics and other drug-related information?

Yes  No

If yes:

20.a. Does this office have an assigned budget to carry out its functions?
Yes  No

20.b. Does this office have the necessary human resources assigned to carry out its functions?
Yes  No

20.c. Is the staff fully trained to fulfill the office mandate?
Yes  No

20.d. Are assessments performed to identify deficiencies in the Observatory’s ability to carry out its functions?
Yes  No
20.d.1. Is there a plan to address the deficiencies (e.g., train staff, hire staff with required skill set, contract out work) within 2-5 years?

Yes  No

21. Which drug demand studies has your country carried out and for which the results have been publicly released during the past five years?

<table>
<thead>
<tr>
<th>Studies</th>
<th>Study carried out and for which the results have been publicly released</th>
<th>Year of most recent survey</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>Priority Studies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survey of secondary school students</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National household surveys (12-64 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Access to patient registers of treatment centers in your country</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recommended Studies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cross-section survey of patients in treatment centers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survey of patients in emergency rooms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survey of higher education students</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survey of populations in conflict with the law</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of drug-related deaths</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survey of other target populations (Please specify: _________________)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others (Please specify: ______________________)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
22. What information related to supply reduction does your country have available?

<table>
<thead>
<tr>
<th>Information</th>
<th>Information available?</th>
<th>Year of most recent information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantification of illicit crop cultivation including crops grown indoors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of seizures of illicit drugs and raw materials for their production</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantities of illicit drugs and raw materials for their production seized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of seizures of controlled chemical substances (precursors)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantities of seized controlled chemical substances (precursors)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of seizures of pharmaceutical products</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantities of seized pharmaceutical products</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons formally charged with drug use, possession and trafficking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons convicted of drug use, possession and trafficking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of laboratories producing illicit plant-based drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of laboratories producing illicit drugs of synthetic origin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Recommended information

<table>
<thead>
<tr>
<th>Information</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical composition of seized drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons formally charged with money laundering</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons convicted of money laundering</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons formally charged with trafficking in firearms, explosives, ammunition and related materials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons convicted of trafficking in firearms, explosives, ammunition and related materials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons formally charged with diversion of chemical substances</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of persons convicted of diversion of chemical substances</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sale price of drugs (for consumers)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others (Please specify: ____________________________)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

23. Has your country carried out and publicly released a study on the economic and social cost of drugs during the past 10 years?

   Yes [ ]   No [ ]

   If yes, please specify the year: ____________________________

24. Does your country disseminate drug demand information to your stakeholders?

   Yes [ ]   No [ ]
If yes:

24.a. Please provide the following information:

<table>
<thead>
<tr>
<th>Stakeholder</th>
<th>Most recent year</th>
<th>Means of sharing information (reports, web postings, presentations)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

25. Does your country disseminate drug supply information to your stakeholders?

Yes  No  

If yes:

25.a. Please provide the following information:

<table>
<thead>
<tr>
<th>Stakeholder</th>
<th>Most recent year</th>
<th>Means of sharing information (reports, web postings, presentations)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CONTEXT OBSERVATIONS FOR RECOMMENDATION 3:


AGENCY AND OFFICIAL PROVIDING INFORMATION:


DEMAND REDUCTION

RECOMMENDATION 4

Develop and implement comprehensive demand reduction policies, plans and/or programs.

26. Does your country have comprehensive demand reduction plans and programs?

   Yes  No

If yes:

26.a. Please indicate if your country has plans and programs in the following areas:

<table>
<thead>
<tr>
<th>Plan/program</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment and rehabilitation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social reinsertion&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Related recovery support services</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

27. Do your country’s plans and programs respond to international minimum standards in demand reduction? (OAS/CICAD, PAHO, UN, or others)

<table>
<thead>
<tr>
<th>Plan/program</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>3</sup> Social reinsertion: Any social intervention with the aim of integrating former or current problem drug users into the community. The three ‘pillars’ of social reintegration are (1) housing, (2) education and (3) employment (including vocational training). May also be referred to as “social re-integration.”
If yes:

27.a. Please explain how your country monitors compliance with these standards.


28. Have your country’s demand reduction plans and programs been designed using available evidence\(^4\), and/or guidelines or recommendations from recognized national and/or international organizations (e.g., OAS/CICAD, UNODC, WHO, PAHO, NIDA, among others)?

Yes  No

If yes, please indicate the type of information or evidence used in the design of the following plans and/or programs:


28.c. Treatment and rehabilitation.


28.e. Related recovery support services.


---

\(^4\) **Available evidence:** Use of evidence, based on which has the best quality. The quality of evidence reflects the extent to which confidence in an estimate of the effect is adequate to support a particular recommendation.
29. Do demand reduction plans and programs include a gender perspective in their design, implementation and evaluation?

Yes  No

If yes, please indicate:

29.a. Prevention.

29.b. Early intervention.

29.c. Treatment and rehabilitation.

29.d. Social reinsertion.

29.e. Related recovery support services.

30. Does your country use current data gathered through demand-related studies (e.g., general population surveys, student surveys, treatment information) to design its demand reduction plans and/or programs?

Yes  No

31. Please indicate which plans and/or programs have been designed utilizing available information regarding the magnitude of and trends in drug use in your country's population:

31.b. Selective prevention.

31.c. Indicated prevention.


31.e. Treatment and rehabilitation.

31.f. Social reinsertion.

31.g. Related recovery support services.

32. Does your country monitor the implementation of demand reduction plans and/or programs?

Yes  No

32a. Please indicate whether your country monitors the implementation of its demand reduction plans and/or programs in the following areas, and provide one example for each applicable area.

<table>
<thead>
<tr>
<th>Type of plan/program</th>
<th>Yes</th>
<th>No</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indicated prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early intervention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment and rehabilitation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social reinsertion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Related recovery support services</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
33. Does your country evaluate the implementation of its demand reduction plans and/or programs?

Yes  No

If yes:

33.a. Please indicate which plans and/or programs are evaluated, the type of evaluation conducted (process, impact, results, cost-benefit), and attach or provide an Internet link to an evaluation report in each applicable area.

<table>
<thead>
<tr>
<th>Type of plan/program</th>
<th>Yes</th>
<th>No</th>
<th>Name of the plan/program and type of evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indicated prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early intervention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment and rehabilitation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social reinsertion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Related recovery support services</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

34. Does your country update its demand reduction plans and/or programs based on current monitoring and evaluation results?

Yes  No

If yes:

34.a. Please attach an example.

35. Has your country adopted a multisectoral approach in its demand reduction plans and/or programs?

Yes  No
If yes:

35.a. Please indicate which sectors and/or actors are involved in your country’s demand reduction plans and/or programs.

CONTEXT OBSERVATIONS FOR RECOMMENDATION 4:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
Design and implement a comprehensive system\(^5\) of evidence-based universal, selective, and indicated prevention programs, with measurable objectives, aimed at distinct target populations, including at-risk groups.

36. Does your country have prevention programs that vary based on the presence of risk factors?

Yes  No

If yes:

36.a. Does your country have universal prevention plans and/or programs?

Yes  No

If yes:

36.a.1. Please describe the universal prevention programs being implemented, including their target groups.

36.b. Does your country have selective prevention plans and/or programs?

Yes  No

If yes:

36.b.1. Please describe the selective prevention programs being implemented, including their target groups.

\(^5\) Comprehensive (prevention) system: organizations and programs that provide addiction prevention services, and are interconnected with several organizations, programs and channels that provide support services.
36.c. Does your country have indicated prevention plans and/or programs?

Yes  No

If yes:

36.c.1. Please describe the indicated prevention programs being implemented, including their target groups.

37. Has your country designed a comprehensive prevention system?

Yes  No

If yes:

37.a. Has your country implemented this comprehensive prevention system?

Yes  No

CONTEXT OBSERVATIONS FOR RECOMMENDATION 5:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
DEMAND REDUCTION

RECOMMENDATION 6
Promote the integration of treatment and recovery plans and programs into the public health system and address drug dependence as a chronic, relapsing disease.

38. Does your country have a network of public health system\(^6\) facilities responsible for public health needs within a given territory, in different regions, states or provinces?

Yes ☐  No ☐

If yes:

38.a. Do these facilities carry out drug use screening?

Yes ☐  No ☐

38.b. Do these facilities have screening instruments in place to detect drug use?

Yes ☐  No ☐

If yes:

38.b.1. Please indicate what instruments are used.

38.c. Do these facilities offer guidance and brief intervention in drug use cases?

Yes ☐  No ☐

---

\(^6\) **Public health system:** Includes all organizations, institutions and resources whose principal objective is to carry out activities designed to improve health. The majority of national health systems include the public, private, traditional and informal sectors. The four primary functions of a health system include: provision of services, generation of resources, financing and management.
38.d. Do these facilities systematically refer persons affected by drug use to treatment?

Yes                   No

If yes:

38.d.1. Please explain the referral process, and the type(s) of treatment providers involved.

39. Does your country’s public health system provide the following treatment services for persons affected by drug use?

<table>
<thead>
<tr>
<th>Service</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residential</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

40. If these services are not provided by the public health system, who provides them (e.g., private institutions, NGOs, religious institutions)?

41. Does your country's public health system provide aftercare services for persons affected by drug use?

Yes                   No

42. If these services are not provided by the public health system, who provides them (e.g., private institutions, NGOs, religious institutions)?

43. Who provides rehabilitation and recovery support services (e.g., community, civil society, NGOs)?
44. Does your country have an accreditation process for its drug treatment centers?

Yes  No  In progress

If yes:

44.a. Please indicate the institution(s) that provides this accreditation, and briefly describe the process.

If in progress:

44.b. Please indicate what stage of development this process is in.

45. Do your country’s public health system facilities offering treatment and rehabilitation services for persons affected by drug use coordinate with other sectors?

Yes  No

If yes:

45.a. Please describe how these facilities and sectors coordinate with each other.

46. Do public health system facilities offering treatment and rehabilitation for persons affected by drug use include monitoring systems for plans and/or programs?

Yes  No

If yes:

46.a. Does your country have trained professionals to implement and manage treatment and rehabilitation monitoring systems?
46.b. Do monitoring systems allow for the collection and organization of information regarding the treatment and rehabilitation plans and/or programs being implemented?

Yes  No

If yes:

46.b.1. Please briefly describe how your country’s monitoring system functions.

CONTEXT OBSERVATIONS FOR RECOMMENDATION 6:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
DEMAND REDUCTION

RECOMMENDATION 7

Facilitate access for drug-dependent persons to a system of drug treatment, rehabilitation, social reintegration, and recovery services that are evidence-based and follow internationally-accepted quality standards.

47. Does your country take actions to facilitate access to treatment, rehabilitation, and social reinsertion for different populations affected by drug use?

Yes  No

If yes:

47.a. Please describe the actions taken.


48. Are treatment and rehabilitation interventions tailored to the population profiles being served?

Yes  No

If yes:

48.a. Please indicate which population profiles are being treated.


49. Are social reinsertion interventions tailored to the population profiles being served?

Yes  No

If yes:

49.a. Please indicate which population profiles are being treated.


CONTEXT OBSERVATIONS FOR RECOMMENDATION 7:


AGENCY AND OFFICIAL PROVIDING INFORMATION:


Demand Reduction

Recommendation 8

Explore the means of offering treatment, rehabilitation, social reinsertion and recovery support services to drug-dependent criminal offenders as an alternative to criminal prosecution or imprisonment.

50. Does your country have national and/or regional legislation, or national/regional administrative guidelines, that create and provide for alternatives to incarceration\(^7\) for drug-dependent criminal offenders?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes, please specify:

50.a. Date that relevant legislation/guidelines were adopted and entered into effect.

50.b. Title of legislation/guidelines.

50.c. Authorities that legislation/guidelines provide for.

50.d. Please provide the operating budget (if applicable).

50.e. Types of alternatives to incarceration offered.

If your country does not currently have alternatives to incarceration, please proceed to context observations box for this Recommendation.

\(^7\) Alternatives to incarceration: vary from jurisdiction to jurisdiction, but most involve suspension of the judicial process provided the offender volunteers to participate in a monitored drug treatment program.
51. Please describe the status of implementation of each of the alternatives to incarceration that your country offers.

52. Does your country have standard operating procedures in place for identifying and selecting candidates for participation in alternatives to incarceration?

Yes  No

If yes:

52.a. Please explain these procedures.

52.b. How does your country maintain records of these candidates?

53. Does your country monitor participant progress in these alternative-to-incarceration programs?

Yes  No

If yes:

53.a. Please describe.

54. Does your country evaluate these alternative-to-incarceration programs?

Yes  No
If yes:

54.a. Please explain your country's system of evaluating each type of programs’ efficiency and effectiveness.

55. Does your country use the outcomes and recommendations from these evaluations to improve its processes and programs for alternatives to incarceration?

Yes  No
RECOMMENDATION 9

Strengthen governmental relationships with academic and research institutions and specialized non-governmental organizations (NGOs), in order to generate evidence on the demand for drugs.

56. Has your country's national drug authority established and maintained cooperative relationships with relevant civil society organizations dealing with drug demand reduction related issues?

Yes  No

If yes:

56.a. Please provide names of several civil society organizations that your country's national drug authority works with and describe the length and nature of the relationship.

56.b. Provide examples of other relevant agencies (e.g., Ministry of Health, Ministry of Foreign Affairs/Relations, law enforcement agencies) that maintain relationships with civil society organizations on demand reduction issues.

57. Has your country's national drug authority established and maintained cooperative relationships with relevant academic and research institutions dealing with drug demand reduction related issues?

Yes  No

If yes:

57.a. Please provide names of several institutions that your country's national drug authority works with and describe the length and nature of the relationship.
58. How do your country's national drug authority and/or relevant agencies use information produced by civil society organizations regarding drug use within and among communities in its demand reduction policies, plans and programs? Please provide an example.

59. How do your country's national drug authority and/or relevant agencies use information produced by academic and research institutions regarding drug use within and among communities in its demand reduction policies, plans and programs? Please provide an example.

60. How do your country's national drug authority and/or relevant agencies work with these institutions and organizations to support and increase their capacity to regularly collect data and produce drug use trend reports? Please provide an example.

CONTEXT OBSERVATIONS FOR RECOMMENDATION 9:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
DEMAND REDUCTION

RECOMMENDATION 10
Promote and strengthen training and continuing education of professionals, technicians and others involved in the implementation of demand reduction activities.

61. Does your country have introductory training programs on all aspects of demand reduction (prevention, treatment/rehabilitation and after care, social reinsertion, and research, monitoring and evaluation) that it offers to personnel involved in the implementation of drug demand reduction activities?

Yes  No

If yes:

61.a. Please indicate who offers these programs, (e.g., academic institutions, Ministry of Health agencies, NGOs, private sector entities, professional groups, hospitals or other medical or scientific facilities, or international organizations), where they are offered, and their frequency.


62. Does your country offer continuing education on all aspects of demand reduction and its continuum of care (prevention treatment/rehabilitation and after care, social reinsertion and monitoring and evaluation) to personnel involved in the implementation of drug demand reduction activities?

Yes  No

If yes:

62.a. Please indicate who offers these programs, where they are offered, and their frequency.
62.b. Is continuing education mandatory for demand reduction officials and/or professionals in your country?

Yes  No

63. Does your country offer certificate level, undergraduate level, and/or graduate level training programs focused on science-based approaches and best practices to drug demand reduction to personnel to increase their knowledge and strengthen their skills in specialized technical or professional fields of expertise?

Yes  No

If yes:

63.a. Please specify the levels and provide examples.


64. Does your country participate in, and thereby make available to its technical experts and professionals, advanced drug demand reduction training programs at the regional and/or international level (e.g., training offered by OAS/CICAD, PAHO, UN, others)?

Yes  No

If yes:

64.a. Please provide details.


65. If these training opportunities are not currently available, please provide a brief explanation of barriers to your country’s participation in such training programs.


66. Does your country's specialized training in drug demand reduction include a gender perspective?

Yes  No

If yes:

66.a. Please briefly describe.

67. Does your country conduct regular reviews/evaluations to ensure that training in drug demand reduction is meeting your country’s need for drug demand reduction personnel (e.g., that personnel are being trained in a range of drug demand reduction fields)?

Yes  No

If yes:

67.a. Who conducts these evaluations, and how frequently are they conducted?

67.b. Please explain how the results of these evaluations are used to improve and update relevant training programs.

CONTEXT OBSERVATIONS FOR RECOMMENDATION 10:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
SUPPLY REDUCTION

RECOMMENDATION 11

Adopt and/or improve comprehensive and balanced measures aimed at reducing the illicit supply of drugs.

68. Is there an approved regulatory framework\(^8\) defining an updated national or federal policy and/or plan for the reduction of the illicit supply of drugs?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes:

68.a. Please provide the following information.

<table>
<thead>
<tr>
<th>Title of the regulation (number, year and name)</th>
<th>Purpose of the regulation</th>
<th>Date the regulation was approved</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

68.b. Please attach text of the regulations, or the pertinent web address.

69. Have national studies, and/or reports been prepared on each element of the illicit supply of drugs?

<table>
<thead>
<tr>
<th>Study/Report</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patterns in the cultivation of illicit crops in your country</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Production potential for illicit drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nature of the raw material for illicit drug production</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other studies aimed at analyzing the illicit supply of drugs situation. Please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

\(^8\) Regulatory framework: The set of established laws and regulations that governs the activities of the institutions responsible for the formulation, development and application of drug supply reduction policies and/or programs.
70. Is the information from national assessments, studies, and/or reports used as a basis for the preparation of national policies and/or plans for the reduction of illicit supply of drugs?

Yes  No

If yes:

70.a. Please complete the following table.

<table>
<thead>
<tr>
<th>Title of the study</th>
<th>Problem identified</th>
<th>Component of the policy, plan, and/or program that addresses the problem identified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

71. Are the risk factors\(^9\) identified in the analytical assessment of the dynamics of the illicit supply of drugs addressed in the plans and/or policies in the reduction of the illicit supply?

Yes  No

If yes:

71.a. Please provide the following information.

<table>
<thead>
<tr>
<th>Title of the study</th>
<th>Risk factor identified</th>
<th>Component of the policy, plan, and/or program that addresses the risk factor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

\(^9\) Risk factors: Risk factors are those conditions that contribute to the emergence or strengthening of illicit activities and/or to the neutralization of law enforcement activities.
CONTEXT OBSERVATIONS FOR RECOMMENDATION 11:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
RECOMMENDATION 12  Adopt and/or improve data collection and analysis mechanisms with a view to carrying out assessments that will facilitate the development of public policies aimed at illicit supply of drugs reduction.

72. Do national authorities gather and/or analyze information from internal and pertinent external sources to implement supply reduction policies for illicit crops used in the production of drugs?

   Yes  No

If yes, please provide the following information:

   72.a. What agencies gather and/or analyze information on the reduction of illicit crops used in the production of drugs?

   

   72.b. What external sources are used?

   

   72.c. Explain the process used to analyze information.

   

73. Does the entity responsible for collection, analysis, and publication of drug data produce a periodic report (at least every 2 years) that consolidates the results and progress made in meeting established indicators for national or federal supply reduction policies and/or plans?

   Yes  No

If yes, please provide the following information:

   73.a. Name of the report.

   

73.b. Frequency of the report.


73.c. Dates of the first and most recent publications.


73.d. Number of times published.


74. Does your country have periodic indicators that can be used to assess your country’s illicit supply of drugs situation?


<table>
<thead>
<tr>
<th>Study/report</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Areas of illicit crops estimated and eradicated. Including productivity indicators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others. Please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

75. Do your country have illicit crop cultivation and drug production estimates?

Yes  No

If yes:

75.a. Please describe.


76. What training activities for relevant actors have been carried out to improve the estimation of illicit crop cultivation and drug production?


77. Have new technologies been used to improve the estimation of illicit crop cultivation and drug production?

Yes  No
If yes:

77.a. Please describe.

---

78. Does your country use mechanisms to disseminate the information gathered?

Yes  No

If yes:

78.a. Please explain the information dissemination mechanism used.

---

CONTEXT OBSERVATIONS FOR RECOMMENDATION 12:

---

AGENCY AND OFFICIAL PROVIDING INFORMATION:
SUPPLY REDUCTION

RECOMMENDATION 13

Promote studies and research that contribute to the early identification and monitoring of new and emerging trends that could provide updated information on the illicit supply of drugs.

79. Does your country have studies on new patterns, dynamics, or changes in the production of illicit crops used in the illicit production of drugs?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Not applicable (please explain)</th>
</tr>
</thead>
</table>

If yes, please provide the following information:

79.a. Title of the study.

79.b. Objective of the study.

79.c. Date completed.

79.d. Web address where the study can be found.

79.e. Key findings of the study.

80. Keeping in mind the dynamics of illicit crops used in the illicit production of drugs, and the importance of international cooperation for their reduction: Has information been shared on the new illicit crop patterns with neighboring countries?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Not applicable (please explain)</th>
</tr>
</thead>
</table>
If yes:

80.a Please explain the mechanism used to share this information.

[Blank Box]

81. Does your country have information on illicit supply of drugs and its connection with other forms of transnational organized crime, such as trafficking in persons, illicit traffic of small and light firearms, ammunition, their parts and explosives?

Yes  No

If yes:

81.a Please explain in general terms how your country applies this information in the decision-making process in the reduction of illicit supply of drugs (e.g., information sharing among law enforcement authorities).

[Blank Box]

CONTEXT OBSERVATIONS FOR RECOMMENDATION 13:

[Blank Box]

AGENCY AND OFFICIAL PROVIDING INFORMATION:

[Blank Box]
RECOMMENDATION 14  

According to the needs of each country, adopt comprehensive measures, such as integral and sustainable alternative development and law enforcement initiatives.

82. Does your country have programs or activities for eradication of illicit crops of coca, cannabis, and/or poppy?

<table>
<thead>
<tr>
<th>Crop</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coca</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poppy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If yes:

82.a. Please indicate, in the following table, the results of activities to eradicate illicit crops used in illicit drug production.

<table>
<thead>
<tr>
<th>Illicit crop</th>
<th>Quantity</th>
<th>Unit of measure *</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>2011</td>
</tr>
<tr>
<td>Coca (manual eradication)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coca (fumigation)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marijuana (Cannabis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poppy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* According to the unit of measure used by your country.

83. Does your country have mechanisms to evaluate programs and/or activities for eradication of illicit crops for illicit drug production?

Yes  No
If yes:

83.a. Please indicate which of these mechanisms are used to evaluate programs and/or activities for eradication of illicit crops for illicit drug production:

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring and regular evaluation of eradication programs or activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular monitoring of new illicit crops</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular review of eradicated areas (replanting)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others. Please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

83.b. Please provide details of the mechanisms reported in the previous question.

84. Does your country have alternative, integral, and sustainable development programs?

Yes

No

If not, please proceed to the context observations box for this Recommendation.

If yes:

84.a. Please provide the following information.

<table>
<thead>
<tr>
<th>Program/project</th>
<th>Duration</th>
<th>Number of families benefited</th>
<th>Number of hectares covered</th>
<th>Budget (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Start date</td>
<td>End date</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

85. Has your country developed or implemented systems to monitor and evaluate alternative, integral, and sustainable development programs?

Yes

No
If yes:

85.a. Please explain the key elements of the system(s).

86. What are the pre-existing conditions for the implementation of alternative, integral, and sustainable development programs? Please explain.

87. In which of the following activities does your country’s community-level civil society participate?

<table>
<thead>
<tr>
<th>Activity</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design of alternative, integral, and sustainable development programs and/or projects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implementation of alternative, integral, and sustainable development programs and/or projects</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If any of the two options is yes:

87.a Please describe the participation.

88. Do the alternative, integral, and sustainable development programs and/or projects include activities that facilitate the population’s access to basic health, education, and sanitation services?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If yes:

88.a. Please provide the information requested in the following table.

<table>
<thead>
<tr>
<th>Program/project</th>
<th>Type of service (*)</th>
<th>Number of families benefited</th>
<th>Budget (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Indicate whether in health, education, or sanitation.
89. Do alternative, integral, and sustainable development projects and/or programs facilitate poverty reduction?

Yes  No

If yes:

89.a. Please provide details on these programs.

<table>
<thead>
<tr>
<th>Name of the poverty reduction program and/or project</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

90. Does your country implement programs and/or projects to prevent the onset of illicit activities related to illicit supply of drugs in vulnerable populations?  

Yes  No

If yes:

90.a. Please provide the requested information in the following table.

<table>
<thead>
<tr>
<th>Program/project name</th>
<th>Program/project objective</th>
<th>Number of Beneficiaries</th>
<th>Budget (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Direct</td>
<td>Indirect</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

10 **Vulnerable populations**: Those sectors or population groups that, due to poverty, ethnic origin, health, age, gender or disability, are unable to develop and improve their circumstances. This vulnerability places such persons at a disadvantage with regard to exercising their full rights and freedoms.
CONTEXT OBSERVATIONS FOR RECOMMENDATION 14:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
SUPPLY REDUCTION

RECOMMENDATION 15
Promote actions to reduce the negative impact on the environment caused by the world drug problem, in accordance with national policies.

91. Does your country carry out research or studies to determine the environmental impact of activities related to the illicit supply of drugs?

Yes ☐ No ☐

If yes:

91.a. Please indicate in the following table the titles and publication dates of the research and/or studies on the subject.

<table>
<thead>
<tr>
<th>Study/research</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

92. Does your country use environmental management tools to address the negative impact of the world drug problem on the environment?

Yes ☐ No ☐

If yes:

92.a. Please indicate the environmental management tools used.

<table>
<thead>
<tr>
<th>Environmental management tool</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental impact studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ecological and economic zoning studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Environmental management plans</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Environmental education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others. Please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

____________________________________
93. Do the institutions responsible for the implementation of drug policies and environmental policies at the various government levels in your country coordinate with each other on the use of environmental management tools to address the negative environmental impact of illicit the supply of drugs?

Yes  No

If yes:

93.a. Please indicate in the following table the institutions involved in the coordination at each level of government.

<table>
<thead>
<tr>
<th>National level</th>
<th>Regional level</th>
<th>Local level</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

94. Has your country signed agreements with donor countries and/or international organizations to evaluate, prevent, and mitigate the negative environmental impacts of the world drug problem?

Yes  No

If yes:

94.a. Please specify in the table below the agreements that your country has signed, through international cooperation to reduce the negative environmental impacts of the world drug problem.

<table>
<thead>
<tr>
<th>Agreement</th>
<th>Country/international organization</th>
<th>Date signed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CONTEXT OBSERVATIONS FOR RECOMMENDATION 15:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
CONTROL MEASURES

RECOMMENDATION 16

Implement programs to prevent and reduce the illicit production of synthetic and plant-based drugs.

95. Does your country have mechanisms to detect and identify laboratories for the illicit production of synthetic and plant-based drugs?

Yes  No

If yes:

95.a. Are they provided for through:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legislation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocols</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Programs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others, please specify:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If yes:

97.a.1 Please attach the respective instruments or provide the relevant web address.


96. Does your country have a national information system that enables gathering information on the laboratories for the illicit production of synthetic or plant-based drugs that have been detected and dismantled?

Yes  No

If yes:

96.a. Please describe its characteristics, including the type of information collected and the agencies that report and/or process the data.


97. Does your country have protocols for the dismantling of laboratories for the illicit production of synthetic and plant-based drugs?

| Yes | No |

If yes:

97.a. Please attach copy of the protocols or provide the relevant web address.

97.b. Do these protocols include the appropriate safety measures that must be adopted to minimize risk for the agents who participate in dismantling the laboratory?

| Yes | No |

If yes:

97.b.1. Please identify the safety measures.

97.c. Do they include actions to minimize damage to the environment?

| Yes | No |

If yes:

97.c.1. Please provide the actions.

98. Does your country have or has your country participated in ongoing training programs for agents responsible for control operations relating to the dismantling of laboratories for the illicit production of drugs?

| Yes | No |
If no:

98.a. Report the training activities conducted or participated in.

In either case:

98.b. Please specify:

98.b.1. What organizations offer the training?

98.b.2. What is the content/curriculum of training offered?

98.b.3. How frequently is training offered?

---

CONTEXT OBSERVATIONS FOR RECOMMENDATION 16:

---

AGENCY AND OFFICIAL PROVIDING INFORMATION:
CONTROL MEASURES

RECOMMENDATION 17

Adopt or strengthen control measures in order to prevent the diversion of controlled chemical substances towards illicit activities.

99. Have the actions specified in Article 3.1.a.IV of the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 been established as criminal offenses?

Yes ☐ No ☐

If yes:

99.a. Please attach copy of the legislation or provide the relevant web address.

If no:

99.b. What steps are being taken to establish these actions as criminal offenses?

100. Does your country have legislation for monitoring controlled chemical substances as provided in Article 12.9 of the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes ☐ No ☐

If yes:

100.a. Please attach copy of the legislation or provide the relevant web address.
101. Please indicate in the following table the control measures stipulated in Article 12.9 of the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 that have been incorporated in domestic legislation:

<table>
<thead>
<tr>
<th>Elements included in the legislation</th>
<th>Specific section (title, article, etc.) containing the element</th>
</tr>
</thead>
<tbody>
<tr>
<td>System for monitoring international trade (brief description)</td>
<td></td>
</tr>
<tr>
<td>Please describe</td>
<td></td>
</tr>
<tr>
<td>Seizure of any controlled substance if there is sufficient evidence that it will be used in the illicit manufacture of narcotics or psychotropic substances</td>
<td></td>
</tr>
<tr>
<td>Notification to authorities and competent services in the interested parties if there are reasons to believe that the importation, exportation, or transit of a controlled substance will be used in the illicit manufacture of narcotics or psychotropic substances</td>
<td></td>
</tr>
<tr>
<td>Require that imports and exports be properly labeled and documented</td>
<td></td>
</tr>
<tr>
<td>Full identification in documented international trade transactions of controlled substances and the parties involved (brief description)</td>
<td></td>
</tr>
<tr>
<td>Retention of supporting documents for international trade for not less than two years</td>
<td></td>
</tr>
</tbody>
</table>

102. Does your country have an updated register of all individuals and corporations handling controlled chemical substances?
102. What information is recorded in the register?

If yes:

103. Is licensing of manufacturers and distributors of controlled chemical substances used to control those substances?

If yes:

104. Are there regular inspections or audits of the establishments of individuals and corporations that have been authorized to handle controlled chemical substances?

If yes:

105. Has your country established administrative and/or civil penalties to punish infractions or violations by individuals or corporations that handle controlled chemical substances?

If yes:
106. Is there a competent authority to coordinate monitoring of controlled chemical substances?

Yes  No

If yes:

106.a. Please indicate in the following table the functions and responsibilities assigned to the competent authority or others that it coordinates. If established in legislation, please attach a copy of it.

<table>
<thead>
<tr>
<th>Responsibilities assigned to the competent authority or others that it coordinates</th>
<th>Name of the responsible authority or authorities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control of international trade (importation, exportation, international transit)</td>
<td></td>
</tr>
<tr>
<td>Control of domestic trade</td>
<td></td>
</tr>
<tr>
<td>Addressing responsibilities with regional organizations</td>
<td></td>
</tr>
<tr>
<td>Addressing responsibilities with international organizations</td>
<td></td>
</tr>
<tr>
<td>Information exchange with authorities in other countries</td>
<td></td>
</tr>
<tr>
<td>Inspection and audit of establishments</td>
<td></td>
</tr>
<tr>
<td>Seizure of irregular shipments</td>
<td></td>
</tr>
</tbody>
</table>

107. Does your country have mechanisms for issuance of timely pre-export notification of controlled substances to other States?

Yes  No
If yes:

107.a. Please specify.

107.b. Please provide the details of pre-export notifications sent in the last two years, using the following format:

<table>
<thead>
<tr>
<th>Year</th>
<th>Destination country for the export</th>
<th>Number of pre-export notifications sent</th>
<th>Number of pre-export notifications sent with sufficient lead time for the importing country to verify the cargoes</th>
<th>Number of pre-export notifications for which response was received within the deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

108. Does your country have mechanisms to respond to timely pre-export notification of controlled substances made by other States?

Yes  No

If yes:

108.a. Please specify.

108.b. Complete the following table with the details of pre-export notifications responded to in the last two years, using the following format:

<table>
<thead>
<tr>
<th>Year</th>
<th>Country issuing the pre-export notifications</th>
<th>Number of pre-export notifications received</th>
<th>Number of pre-export notifications responded to in a timely manner</th>
<th>Number of pre-export notifications received after the shipment of cargo or deadline for response</th>
<th>Number of pre-export notifications not responded to within the allotted timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CONTEXT OBSERVATIONS FOR RECOMMENDATION 17:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
RECOMMENDATION 18

**CONTROL MEASURES**

Adopt or strengthen control measures to prevent the diversion of narcotics, psychotropic substances, pharmaceutical products with psychoactive properties and those used in the production of synthetic drugs.

109. Does your country have legislation for the control of narcotics, psychotropic substances, and psychoactive pharmaceutical products?

Yes  No

If yes:

109.a. Please attach copy of the legislation or provide the relevant web address.

109.b. Please indicate in the following table which control elements contained in the conventions are included in your country’s legislation:

<table>
<thead>
<tr>
<th>Elements included in the legislation</th>
<th>Specific section (title, article, etc.) that contains the element</th>
</tr>
</thead>
<tbody>
<tr>
<td>A licensing system for manufacture, trade, and distribution</td>
<td></td>
</tr>
<tr>
<td>A medical prescriptions system (except for preparations exempt in the conventions)</td>
<td></td>
</tr>
<tr>
<td>Requirement to keep records of each movement of controlled substances and products and to submit them</td>
<td></td>
</tr>
<tr>
<td>to the appropriate authority</td>
<td></td>
</tr>
<tr>
<td>Regulations for advertising and labeling</td>
<td></td>
</tr>
<tr>
<td>Control through individual authorizations for each international trade action (import or export)</td>
<td></td>
</tr>
<tr>
<td>Inspection regime for manufacturers, exporters, importers, wholesalers, and retailers who deal in</td>
<td></td>
</tr>
<tr>
<td>narcotics, psychotropic substances, and psychoactive pharmaceutical products in any environment</td>
<td></td>
</tr>
<tr>
<td>(including ports and free zones)</td>
<td></td>
</tr>
</tbody>
</table>
110. Is there a national authority responsible for coordinating activities for the control of narcotics, psychotropic substances, and pharmaceutical products with psychoactive properties?

Yes  No

If yes:

110.a. What is its placement within the organizational structure?


110.b. What are its functions and responsibilities?


110.c. Please attach copy of relevant legislation if the functions and responsibilities are expressly set out by law or provide the relevant web address.


111. Does your country have mechanisms to estimate drug requirements?

Yes  No

If yes:

111.a. Please describe.


111.b. Does the system supply the data called for in Article 19 of the Convention of 1961?

Yes  No
If yes:

111.b.1 Please describe.

If yes:

112. Does domestic legislation authorize administrative and/or civil penalties for infractions or violations of the regulations by medical professionals, professional managers, administrators, and/or legal representatives of establishments that work with narcotics, psychotropic substances, and psychoactive pharmaceutical products?

Yes  No

If yes:

112.a. Please list them below.

112.b. Please attach copy of the legislation or provide the relevant web address.

CONTEXT OBSERVATIONS FOR RECOMMENDATION 18:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
RECOMMENDATION 19
Ensure the adequate availability of narcotics needed for medical and scientific use.

113. Does your country periodically evaluate the availability of narcotics and psychotropic substances?

Yes  No

If yes:

113.a. Do the evaluations include an analysis of impediments to adequate availability?

Yes  No

114. If there are problems with ensuring the adequate availability of narcotics and psychotropic substances for medical and scientific use, has your country taken or is it planning to take steps to correct the situation?

Yes  No

If yes:

114.a. Please indicate what steps are planned or taken.

____________________________________________________________________

CONTEXT OBSERVATIONS FOR RECOMMENDATION 19:

____________________________________________________________________

AGENCY AND OFFICIAL PROVIDING INFORMATION:
RECOMMENDATION 20  
Strengthen national organizations for the control of illicit drug trafficking and related crimes.

115. Does your country have periodic evaluations of the strengths and weaknesses of organizations responsible for the control of illicit drug trafficking and related crimes?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes:

115.a. Please specify the organizations, the aspects covered, and the frequency of the evaluations.


115.b. What is the scope of the evaluations?


116. Does your country have ongoing training programs for stakeholders involved in the control of illicit drug trafficking and related crimes?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If no:

116.a. Please report the training activities conducted or participated in.


In either case:

116.b. Please specify:

118.b.1. What organizations offer the training?
116.b.2. What is the content/curriculum of training offered?


116.b.3. How frequently is training offered?


117. Does your country have formal information exchange mechanisms among agencies responsible for the control of illicit drug trafficking and related crimes?

Yes  No

If no:

117.a. Please indicate whether there are informal information exchange mechanisms.


In either case:

117.b. Please specify the characteristics and the agencies covered in these mechanisms.


118. Does your country have law enforcement legislation or regulations to prevent illicit drug trafficking:

118.a. By air?

Yes  No

If yes:

118.a.1 Please attach copy of the legislation or provide the relevant web address.


118.b. By sea?

Yes  No

If yes:

118.b.1 Please attach copy of the legislation or provide the relevant web address.

118.c. By land?

Yes  No

If yes:

118.c.1 Please attach copy of the legislation or provide the relevant web address.

119. Does your country have regular law enforcement plans to prevent illicit drug trafficking?

Yes  No

If yes:

119.a. Please describe their content and frequency.

120. Does your country have laws or regulations that provide for the final and secure disposal of seized drugs?

Yes  No
If yes:

120.a. What are their characteristics?

120.b. Do the provisions include proper recording of the final destination of seized substances?

120.c. Do they include environmental precautions to be taken for different types of substances?

120.d. Please attach copy of the current legislation and regulations or provide the relevant web address.

---

CONTEXT OBSERVATIONS FOR RECOMMENDATION 20:

---

AGENCY AND OFFICIAL PROVIDING INFORMATION:
## RECOMMENDATION 21

Identify new trends and patterns regarding illicit drug trafficking and related crimes.

121. Does your country have updated analyses on recent trends in illicit drug trafficking and related crimes?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes:

121.a. What topics do they cover?

121.b. How frequently are they done?

121.c. Are these studies published, or disseminated in an informal manner?

122. Have regulations been updated or are there plans to update them based on the identification of new trends in illicit drug trafficking and related crimes?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes:

122.a. Please describe.
CONTEXT OBSERVATIONS FOR RECOMMENDATION 21:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
CONTROL MEASURES

RECOMMENDATION 22
Promote improvements in information systems on illicit drug trafficking and related crimes.

123. Does your country have statistical information at the national level on illicit drug trafficking and related crimes?

   Yes  No

If yes:

123.a. What are the database variables on which data is collected?


123.b. Which agencies provide the information?


123.c. Are there standardized methods for gathering and validating the data provided by the various agencies?

   Yes  No

If yes:

123.c.1. Please describe.


124. Does your country have a national early warning system on new behaviors of criminal organizations involved in illicit drug trafficking?

   Yes  No
If yes:

124.a. What does it consist of?


124.b. What agencies does it include?


124.c. Please describe how it works.


125. Does your country carry out studies and technical research on illicit drug trafficking and related crimes?

Yes  No

If yes:

125.a. How are they circulated? (published or limited distribution)


125.b. What is their scope?


125.c. Provide title, date, content, and methodology of studies carried out.


126. Does your country have studies on impurity profiles and characterization of drugs\textsuperscript{11}?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes:

126.a. What is their scope and frequency?

126.b. What techniques are used in the analysis?

126.c. Are there computerized registers of physical and chemical information on seized substances, which would be obtained from these studies?

CONTEXT OBSERVATIONS FOR RECOMMENDATION 22:

AGENCY AND OFFICIAL PROVIDING INFORMATION:

\textsuperscript{11} Drug characterization and impurity profiling: refers to the use of scientific laboratory information in support of law enforcement operation work, and is aimed at establishing links between drug samples. It consists of the systematic collection and sharing, in a standardized form, of physical and chemical information on a drug seizure, including the analysis and use of trace impurities to link different drug samples.
RECOMMENDATION 23

Adopt measures for effective cooperation in criminal investigations, investigation procedures, collection of evidence, and the exchange of intelligence information among countries, assuring due respect for the various national legal systems.

127. Does your country have mechanisms for the secure and effective exchange of intelligence information in the investigation of cases involving illicit drug trafficking and related crimes?

Yes  No

127.a. Please describe.

128. Does your country have formal mechanisms for coordination and exchange of information and best practices for the prevention, investigation, and control of activities related to illicit drug trafficking via the Internet?

Yes  No

If no:

128.a. Please indicate if there are informal information exchange systems.

In either case:

128.b. Please specify their characteristics and the agencies (domestic, foreign or international) involved.
129. Does your country offer or participate in training workshops on intelligence information exchange in the investigation of cases involving illicit drug trafficking and related crime?

Yes [ ] No [ ]

If no:

129.a. Please report the training activities offered or participated in.

In either case:

129.b. Please specify:

129.b.1. What organizations offer the training?

129.b.2. What is the content/curriculum of training offered?

129.b.3. How frequently is training offered?

130. Does your country offer or participate in training activities on the application of special investigation techniques and the management of the chain of custody for evidence in cases of illicit drug trafficking and related crimes?

Yes [ ] No [ ]

If no:

130.a. Please report the training activities offered or participated in.
In either case:

130.b. Please specify:

130.b.1. What organizations offer the training?

130.b.2. What is the content/curriculum of training offered?

130.b.3. How frequently is training offered?

131. Does your country have regulatory frameworks and/or operational guidelines for the investigation of all assets during illicit drug trafficking cases?

Yes  No

If yes:

131.a. Please identify the frameworks/guidelines?

131.b. Please attach copy of the existing regulation or guidelines or provide the relevant web address.

CONTEXT OBSERVATIONS FOR RECOMMENDATION 23:

AGENCY AND OFFICIAL PROVIDING INFORMATION:
RECOMMENDATION 24

Adopt or strengthen, as applicable, control measures for the illicit trafficking of firearms, munitions, explosives, and other related materials associated with illicit drug trafficking.

132. Has your country criminalized the illicit manufacture of and trafficking in firearms, ammunition, explosives, and other related materials?

| Yes | No |

134.a. Please describe.

133. Does your country have mechanisms to eliminate loss or diversion in instances of licit trade?

| Yes | No |

If yes:

133.a. Please identify the mechanisms.

134. Does your country have controls for the manufacturing of and trafficking in firearms, ammunition, explosives, and other related materials?

| Yes | No |

If yes:

134.a. Please identify the controls in place.
135. When manufacturing firearms, ammunition, explosives, and other related materials are manufacturers required to make appropriate markings with the information specified in Article 6 of the Inter-American Convention against the Illicit Manufacturing of and Trafficking in Firearms, Ammunition, Explosives, and Other Related Materials of 1997?

Yes  No

136. Does your country have a system of export, import, and international transit licenses or authorizations for transfers of firearms, ammunition, explosives, and other related materials?

Yes  No

136.a. Please describe.

137. Is there a national authority responsible for coordinating controls on the illicit manufacturing of and trafficking in firearms, ammunition, explosives, and other related materials?

Yes  No

If yes:

137.a. What is its placement in the organizational structure?

137.b. What are its duties and responsibilities?
138. Does your country have a registry of firearms, ammunition, explosives, and other related materials seized during illicit drug trafficking operations/actions?

Yes  No

If yes:

138.a. What type of information is recorded? Please describe.

________________________________________________________________________

_____________________________________

CONTEXT OBSERVATIONS FOR RECOMMENDATION  24:

________________________________________________________________________

AGENCY AND OFFICIAL PROVIDING INFORMATION:

________________________________________________________________________

________________________________________________________________________
CONTROL MEASURES

RECOMMENDATION 25

Establish, update, or strengthen legislative and institutional frameworks in matters of prevention, detection, investigation, and prosecution of money laundering.


Yes  No

If yes:

139.a. Please attach copy of the legislation or provide the relevant web address.

If no:

139.b. Are bills pending for money laundering criminalization?

Yes  No

If yes:

139.b.1. Please describe.

If no:

140. Does your country have regulations for the prevention and control of money laundering?

Yes  No
If yes:

140.a. Do the regulations follow the Financial Action Task Force (FATF) recommendations?

140.b. Please attach copy of the legislation or provide the relevant web address.

If your country does not have regulations that conform with the international recommendations:

140.c. Is your country implementing or is it planning to implement actions to bring the current money laundering regulations in line with international recommendations?

Yes  No

If yes:

140.c.1. Please describe.

141. Does your country have a Financial Intelligence Unit?

Yes  No

If yes:

141.a. What is its placement in the organization structure?

141.b. What are its duties and responsibilities?

141.c. Is the Financial Intelligence Unit a member of the Egmont Group?
141.d. Please attach copy of the legislation governing its responsibilities and duties or provide the relevant web address.

If there is no Financial Intelligence Unit:

141.e. Does your country plan to establish one?

Yes  No

141.e.1. Please describe.

142. Does your country have regulations for forfeiture of assets related to money laundering?

Yes  No

If yes:

142.a. Do the existing regulations for forfeiture of assets related to money laundering operators include provisional measures such as freezing and embargo to prevent the use, transfer, or disposal of said assets?

Yes  No

142.a.1. Please describe.

142.b. Please attach copy of the legislation or provide the relevant web address.
**CONTEXT OBSERVATIONS FOR RECOMMENDATION 25:**

<table>
<thead>
<tr>
<th>Agency and Official Providing Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
RECOMMENDATION 26

Create or strengthen, in accordance with national legislation, the competent national organizations for the management of seized and/or forfeited assets, and the disposition of forfeited assets.

143. Does your country have an organization responsible for the management/disposal of seized and/or forfeited assets?

Yes  No

If yes:

143.a. Is there a single organization responsible for seized/forfeited assets in illicit drug trafficking and money laundering cases, or are there separate organizations with authority for each of these crimes?

143.b. What is its placement in the organizational structure?

143.c. What are its duties and responsibilities?

143.d. Please attach copy of the legislation governing its responsibilities and duties or provide the relevant web address.

144. Does your country have regulations for the management and disposal of seized and/or forfeited assets?

Yes  No
If yes:

144.a. Please attach copy of the legislation or provide the relevant web address.

---

145. Does your country have or has participated in training programs for the management of seized and/or forfeited assets?

Yes  No

If no:

145.a. Please report the training activities conducted or participated in.

---

In either case:

145.b. Please specify:

145.b.1. What organizations offer the training?

---

145.b.2. What is the content/curriculum of training offered?

---

145.b.3. How frequently is training offered?

---

CONTEXT OBSERVATIONS FOR RECOMMENDATION 26:

---

AGENCY AND OFFICIAL PROVIDING INFORMATION:

---
INTERNATIONAL COOPERATION

**RECOMMENDATION 27**

Reaffirm the principle of cooperation contained in international instruments\(^{12}\) to address the world drug problem, through actions to ensure compliance and effectiveness.

146. Has your country ratified the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

- [ ] Yes
- [ ] No

If yes:

146.a. Does your country have laws or other legal provisions that permit the extradition of citizens for offenses criminalized in accordance with Article 3.1 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

- [ ] Yes
- [ ] No

If yes:

146.a.1. Please indicate and specify: law or legal provision and corresponding articles or regulations.

146.b. Is extradition from your country contingent upon the existence of a treaty?

- [ ] Yes
- [ ] No

---

If no:

146.b.1. Does your country recognize the offenses criminalized in accordance with Article 3.1 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 as subject to extradition?

Yes  No

If yes:

146.b.1.a. Please indicate and specify: law or legal provision and corresponding articles or regulations.

146.c. Does your country try persons whose extradition has been denied on the grounds stipulated in Article 4.2.a of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No

If yes:

146.c.1. Please indicate and specify: law or legal provision and corresponding articles or regulations.

146.d. If your country does not extradite for this type of crime, but has established jurisdiction over it in accordance with Article 4.2.b of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988, does it try the alleged offender?

Yes  No
If yes:

146.d.1. Please indicate and specify: law or legal provision and corresponding articles or regulations.

If your country has ratified either of the Conventions in question 147, please respond to the following questions regarding MONEY LAUNDERING:


Yes  No

If the legal basis is not the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988:

147.b. Is extradition contingent upon the existence of a treaty?

Yes  No
If no:

147.b.1. Does your country recognize the offenses criminalized in accordance with Article 6 of the United Nations Convention against Transnational Organized Crime of 2000?

- Yes
- No

If yes:

147.b.1.A. Please indicate and specify: law or legal provision and corresponding articles or regulations.

If yes:

147.c. If the requesting state so requests, does your country try persons whose extradition has been denied on grounds of nationality?

- Yes
- No

If yes:

147.c.1. Please indicate and specify: law or legal provision and corresponding articles or regulations.

148. If your country has ratified either of the Conventions in question 147, please respond to the following questions regarding ILICIT DRUG TRAFFICKING:\(^{13}\):

148.a. Does your country have laws or other legal provisions to provide reciprocal judicial assistance to third party States in investigations, trials, and legal proceedings for illicit drug trafficking?

- Yes
- No

\(^{13}\) Illicit drug trafficking is as referred to in Article 3, paragraphs 1 and 2 of the United Nations Convention, Vienna, 1988.
If yes:

148.a.1. Please indicate and specify: law or legal provision and corresponding articles or regulations.

148.b. Does your country have laws or other legal provisions to provide reciprocal judicial assistance to third party States in investigations, trials, and legal proceedings for money laundering?

Yes  No

If yes:

148.b.1. Please indicate and specify: law or legal provision and corresponding articles or regulations.

148.c. Does the spectrum of judicial assistance include any of the following?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking evidence or statements from persons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effecting service of judicial documents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Executing searches and seizures and preventive embargoes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Examining objects and sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Providing information and evidentiary items and expert reports</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Providing original or certified copies of relevant documents and records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identifying or tracing proceeds, property, instrumentalities or other items for evidentiary purposes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facilitating the voluntary appearance of persons in the requesting State</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
149. If your country has ratified either of the Conventions in question 147, please respond to the following questions regarding ASSETS:

149.a. Has your country adopted measures to enable confiscation of proceeds derived from illicit drug trafficking or property of equal value, and the materials and equipment or other instrumentalities used in or intended for use in any manner in the crime of illicit drug trafficking?

   Yes  No

   If yes:

   149.a.1. Please describe them briefly.


149.b. Among the measures adopted to enable confiscation of proceeds derived from illicit drug trafficking or property of equal value, and the materials and equipment or other instrumentalities used in or intended for use in any manner in the crime of illicit drug trafficking, are competent authorities authorized to identify, detect, place a preventive embargo on, or seize the proceeds, assets, instrumentalities or any other elements stipulated in Article 3.1 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 or Article 12.1 of the United Nations Convention against Transnational Organized Crime of 2000?

   Yes  No

   149.b.1. Please describe.


149.c. Do the measures adopted to enable confiscation of proceeds derived from illicit drug trafficking or property of equal value, and the materials and equipment or other instrumentalities used in or intended for use in any manner in the crime of illicit drug trafficking respect the rights of bona fide third parties?

   Yes  No
150. Has your country ratified the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No

If yes:

150.a. Does your country have communication channels between its competent agencies and services to facilitate the rapid and secure exchange of information on all aspects of the offenses established pursuant to Article 3.1 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No

If yes:

150.a.1. Please provide a brief description.

150.b. Does your country have mechanisms for administrative cooperation with agencies and services in other States in inquiries on the identity, whereabouts, and activities of persons allegedly linked to drug trafficking; the movement of proceeds or assets used to commit the crime of illicit drug trafficking; and movement of narcotic drugs, psychotropic substances, or other substances in the annexes of lists 1 and 2 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No

If yes:

150.b.1. Please provide a brief description.
150.c. Does your country have laws or other legal provisions to permit use of controlled delivery of narcotics and psychotropic substances in order to identify persons implicated in the crime of illicit drug trafficking?

Yes  No

If yes:

150.c.1. Please indicate and specify: law or legal provision and articles or regulations.

150.d. Has a central authority been designated pursuant to Article 6 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No

150.e. Has a central authority been designated pursuant to Article 7 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No

150.f. Has a central authority been designated pursuant to Article 17 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988?

Yes  No


Yes  No
151.a. When manufacturers produce firearms, are they required by law to mark them adequately with the name of the manufacturer, the place of manufacture, and the series?

Yes  No

151.b. Is there a legal obligation for proper marking of imported firearms to permit identification of the importer's name and address?

Yes  No

151.c. Is there a legal obligation for proper marking of any firearm confiscated or seized for illicit manufacture or trafficking?

Yes  No

151.d. Has an entity or single contact point been designated pursuant to Article XIV.2 of the Inter-American Convention against Illicit Manufacturing of and Trafficking in Firearms, Ammunition, Explosives, and Other Related Materials of 1997?

Yes  No

151.e. Has a central authority been designated pursuant to Article 13 of the Protocol against the Illicit Manufacturing of and Trafficking in Firearms, their Parts and Components, and Ammunition, which supplements the United Nations Convention against Transnational Organized Crime of 2000?

Yes  No

152. Has your country ratified the Inter-American Convention on Mutual Assistance in Criminal Matters of 1992?

Yes  No
If yes:

152.a. Has a central authority been designated pursuant to Article 3 of the Inter-American Convention on Mutual Assistance in Criminal Matters of 1992?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

153. Please provide the following figures:
Number of outgoing extradition requests made regarding illicit drug trafficking and money laundering cases.

<table>
<thead>
<tr>
<th>Outgoing extradition requests made regarding illicit drug trafficking cases</th>
<th>Outgoing extradition requests made regarding money laundering cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>2013</td>
</tr>
</tbody>
</table>

154. Please provide the following figures:
Number of incoming extradition requests made regarding illicit drug trafficking and money laundering cases.

<table>
<thead>
<tr>
<th>Incoming extradition requests regarding illicit drug trafficking cases</th>
<th>Incoming extradition requests regarding money laundering cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>2013</td>
</tr>
</tbody>
</table>

155. Please provide the following figures:
Number of outgoing extradition requests answered regarding illicit drug trafficking and money laundering cases.

<table>
<thead>
<tr>
<th>Outgoing extradition requests answered regarding illicit drug trafficking cases</th>
<th>Outgoing extradition requests answered regarding money laundering cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>2013</td>
</tr>
</tbody>
</table>
156. Please provide the following figures:
Number of incoming extradition requests answered regarding illicit drug trafficking and money laundering cases.

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incoming extradition requests answered regarding illicit drug trafficking cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incoming extradition requests answered regarding money laundering cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

157. Please provide the following figures:
Number of requests for reciprocal judicial assistance made regarding illicit drug trafficking and money laundering cases.

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requests for reciprocal judicial assistance made regarding illicit drug trafficking cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Requests for reciprocal judicial assistance made regarding money laundering cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

158. Please provide the following figures:
Number of requests for reciprocal judicial assistance answered regarding illicit drug trafficking and money laundering cases.

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requests for reciprocal judicial assistance answered regarding illicit drug trafficking cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Requests for reciprocal judicial assistance answered regarding money laundering cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CONTEXT OBSERVATIONS FOR RECOMMENDATION 27:


AGENCY AND OFFICIAL PROVIDING INFORMATION:
OUTLINE FOR THE REFERENCE DOCUMENT (OPTIONAL)

The reference document (optional), prepared by each member state and transmitted by the National Coordinating Entity (NCE) at the onset of the round of the Multilateral Evaluation Mechanism (MEM), provides countries with the opportunity to briefly describe their drug control status. It should be concise and address both the achievements made by the country as well as the difficulties it faces in addressing the problem.

The purpose of the document is to provide the Governmental Expert Group (GEG) with the necessary understanding of the national situation in confronting the drug problem so as to accurately draft national evaluations. It is, therefore, advisable that countries provide information that best contextualizes their efforts.

In order to ensure that GEG Experts are provided with the most relevant information, it is recommended that countries adhere to the following outline in the development of the reference document in no more than 3 pages.

I. **Introduction:**

The short introduction to the document should:

- Include a published map of the country;
- Provide a snapshot of the geographical, economic, and social situation in the country;
- Give a general description of the country’s political system;
- Provide a description of the country’s drug strategy; and
- Give a brief history of the drug problem and any particular challenges or threats to the national drug strategy

II. **General Description of the Country’s Efforts to Confront the World Drug Problem**

This chapter should:

a) describe the priorities, any emerging challenges and any threats faced by the country in confronting the drug problem, within the following suggested sub-sections:

- National Anti-Drug Plan and National Drug Authority/ Institutional Strengthening
- Demand Reduction
- Supply Reduction
- Control Measures
- International Cooperation

b) include information about any new drugs detected, or sudden increases in the use of available drugs, as well any new routes of drug administration detected.

---

14 The country could also publish a list of relevant websites that contain additional information about the country’s anti-drug strategy.
III. **Conclusion:**

The conclusion should provide an overview of the country’s approach to anti-drug efforts. Countries should indicate the specific areas that have received more attention and those that have been prioritized. In the conclusion, countries should also mention and discuss any key achievements they have attained. Countries should also use the conclusion to provide the GEG with any information not contained in the MEM Survey, which it deems useful to better understand the country’s efforts.